Clinical Trial Update: A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating pembrolizumab with or without maintenance olaparib as first-line treatment in metastatic squamous non-small cell lung cancer has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Squamous Cell, Non-small-cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2024-11-06